Vega BioImaging
Vega BioImaging is a Montreal-based precision medicine company that combines patented functionalized nanobeads, optical imaging, and AI image analysis to deliver quantitative multiplexed cancer biomarker detection, serving pharmaceutical companies developing oncology therapeutics and clinical/research laboratories.
- Company typePrivate
- Founded2021
- HeadquartersMontréal, Canada
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Vega BioImaging does
Vega BioImaging is a Montreal-based precision medicine company founded in 2021 that develops a cancer diagnostic platform for quantitative, multiplexed biomarker detection. The company targets pharmaceutical and biotechnology firms developing targeted oncology therapeutics, as well as clinical and research laboratories, addressing companion diagnostic error rates that range from 7% to 30% depending on pathology. Its only disclosed enterprise customer is 9Bio Therapeutics, with whom it co-develops companion diagnostics for antibody-drug conjugate candidates in head, neck, and metastatic breast cancers.
The platform combines three integrated components: (1) a Protein Kit using patented functionalized alloy nanobeads that bind specific cancer biomarkers with distinct optical signatures, delivering 10x greater sensitivity than traditional fluorescent markers and enabling direct protein detection without secondary antibodies; (2) an Advanced Optical Scanner based on light-scattering and dark-field microscopy for single-particle level detection compatible with standard histopathology workflows; and (3) AI-based software that automates image analysis, quantifies biomarker expression, and predicts treatment response using machine learning. The technology originated from research at Polytechnique Montréal (co-founder Michel Meunier) and has been clinically validated in collaboration with CRCHUM (Dr. Dominique Trudel, Dr. Roula Albadine).
Vega generates revenue through three streams: companion diagnostics development services for pharmaceutical clients (professional services), sale of proprietary diagnostic kits and optical scanners (hardware), and quantitative multiplexed biomarker analysis services to support clinical trial patient selection and monitoring (professional services). Pricing is quote-based with multi-year enterprise contracts, and the go-to-market is direct B2B sales targeting pharma/biotech and laboratory buyers, supplemented by research collaborations with academic and clinical partners such as CRCHUM, Polytechnique Montréal, Université de Montréal, and the pan-Canadian Nanomedicine Innovation Network (NMIN). To date, capital has come primarily from non-dilutive Quebec sources (Centech, Front Row Ventures, Axelys, CQDM's Partenar-IA program in partnership with IVADO) totaling roughly CAD $2.07M, including the $0.9M grant supporting the May 2025 $1.8M 9Bio initiative.
Vega BioImaging firmographics
Firmographics- Name
- Vega BioImaging
- Legal name
- Vega BioImaging
- Website
- https://vegabioimaging.com
- Company type
- Private
- Founded year
- 2021
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Vega BioImaging is a Montreal-based precision medicine company that combines patented functionalized nanobeads, optical imaging, and AI image analysis to deliver quantitative multiplexed cancer biomarker detection, serving pharmaceutical companies developing oncology therapeutics and clinical/research laboratories.
- Ownership category
- akta.pro rank
Vega BioImaging industry classification
Industry- Product category
- Cancer Diagnostics
- NAICS
- In-Vitro Diagnostic Substance Manufacturing (325413), Analytical Laboratory Instrument Manufacturing (334516), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835), Laboratory Analytical Instruments (3826), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Molecular Pathology & Tissue Biomarkers (IHC/ISH, digital pathology-linked markers) (HLAAAMAI)
- akta.pro secondary industries
- Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays) (HLAAALAL), Biosensors & Lab-on-Chip (BioMEMS) (HDAHALAK)
Keywords
Where Vega BioImaging is headquartered
LocationHeadquarters
- HQ city
- Montréal
- HQ country
- Canada
- HQ region
- North America
Offices1 record
Markets served
Vega BioImaging business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
Revenue model
- Companion Diagnostics Development Services: Vega develops tailored companion diagnostics (CDx) for pharmaceutical companies to support clinical trials and drug development. Services include patient stratification, biomarker validation, and treatment response prediction for targeted oncology therapies.
- Diagnostic Kits and Hardware: Sale of proprietary Protein Kits containing functionalized nanobeads for biomarker detection, and Advanced Optical Scanners for high-resolution imaging. Products designed for research and clinical applications in cancer diagnostics.
- Clinical Trial Support Services: Quantitative multiplexed biomarker analysis services for patient selection and monitoring in clinical trials, reducing trial errors and accelerating development timelines for pharmaceutical partners.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Enterprise B2B pricing for pharmaceutical and laboratory customers |
Go-to-market motion3 records
Distribution channels2 records
Marketing channels3 records
Vega BioImaging product offering
Product offeringCore offering
Vega BioImaging sells an integrated cancer diagnostic platform consisting of a Protein Kit containing patented functionalized alloy nanobeads, an Advanced Optical Scanner based on light-scattering microscopy, and AI-Based Software for automated biomarker quantification. The company also provides companion diagnostic development services and clinical trial support to pharmaceutical companies and clinical/research laboratories for quantitative, multiplexed biomarker detection in oncology.
Product overview
Vega BioImaging offers a comprehensive cancer diagnostic platform comprising three integrated components: the Protein Kit (using patented functionalized nanobeads for biomarker detection), the Advanced Optical Scanner (high-resolution light-scattering imaging system), and AI-Based Software (automated machine learning image analysis). This unified platform enables quantitative, multiplexed biomarker detection in tissue samples, overcoming limitations of traditional immunohistochemistry by providing enhanced sensitivity, stability, and accuracy in cancer subtyping and treatment response prediction.
Differentiator
Problem solved
Functional benefit
Products and services
- Protein Kit The Vega BioImaging Protein Kit enables quantitative, multiplexed detection of cancer biomarkers using patented functionalized nanobead technology. It provides highly sensitive, reproducible analysis of protein expression in tissue samples for research and clinical applications, targeting pharmaceutical companies, clinical laboratories, and biotech researchers.
- Advanced Optical Scanner The Vega BioImaging Optical Scanner provides high-resolution imaging for detection of multiple cancer biomarkers using advanced light-scattering and dark-field microscopy. It captures and visualizes nanobead signals in tissue samples with single-particle level sensitivity and precision, targeting clinical and research laboratories performing cancer diagnostics.
- AI-Based Software Vega BioImaging's AI-Based Software offers automated image analysis for identification and quantification of cancer biomarkers using advanced machine learning algorithms. It processes images autonomously, identifying biomarkers and measuring expression with high precision, and produces objective readouts of cancer subtype analysis for pharmaceutical and laboratory users.
- Companion Diagnostics Development Services Tailored companion diagnostic (CDx) development services for pharmaceutical companies, including patient stratification, biomarker validation, and treatment response prediction to support clinical trials and regulatory approval of targeted oncology therapies.
- Clinical Trial Support Services Quantitative multiplexed biomarker analysis services for patient selection and monitoring in clinical trials, designed to reduce trial errors and accelerate development timelines for pharmaceutical partners.
Quantifiable outcome
- 10x greater sensitivity than traditional fluorescent markers
- +3 more outcomes
Companies that use Vega BioImaging
Customer profileNamed customers1 record
Segments4 records
Ideal customer profiles4 records
Vega BioImaging technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability6 records
Feature4 records
Vega BioImaging partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core and minor.
- 9Bio Therapeuticscore$1.8M collaborative initiative in targeted oncology therapies combining Vega's diagnostic platform with 9Bio's antibody-drug conjugate technology. Focus on developing companion diagnostic for head, neck, and metastatic breast cancer treatments. Project supported by $0.9M Quebec government grant through CQDM's Partenar-IA program.
- CRCHUM (Centre de recherche du CHUM)coreResearch collaboration with Centre Hospitalier de l'Université de Montréal for early validation of Vega's diagnostic technology. Clinical validation studies showing platform can differentiate protein expression with greater precision than traditional methods.
- Polytechnique MontréalcoreAcademic partner and origin of Vega's technology through university research. Co-founder Michel Meunier is professor of Engineering Physics at Polytechnique Montreal. Company founded from university research in biomedical nanotechnology.
- Université de MontréalminorAcademic partnership for clinical validation with researchers including Dr. Dominique Trudel (Associate Professor) and Dr. Roula Albadine (Associate Professor/pathologist at CHUM) supervising clinical application of diagnostic platform.
- NMIN (Pan-Canadian Nanomedicine Innovation Network)minorCSO Jennyfer Zapata chairs the Executive Committee of Highly Qualified Personnel (HQP) in the national nanomedicine network, facilitating industry collaboration and research partnerships.
Scale indicators4 records
Recent moves6 records
Expansion highlights6 records
Vega BioImaging competitors and assessment
Company assessmentBroad incumbents
- Revvity (formerly PerkinElmer Life Sciences): Revvity offers the Vectra and Phenoptics multiplexed tissue imaging workflow, IHC and ISH reagents, and clinical trial services — a broad incumbent competing with Vega across reagents, instruments, AI software, and CDx services.
- Abcam: Abcam supplies the large catalog of IHC-validated antibodies and recombinant reagents that feed into existing pathology workflows, positioning it as a complementary/competing reagent provider that benefits from — or competes with — Vega's nanobead reagents.
- Roche Diagnostics (Ventana): Roche's Ventana platform is the market-leading IHC and companion diagnostics franchise with installed instruments in most clinical pathology labs worldwide — the dominant incumbent Vega must displace or complement for oncology CDx workflows.
- Bio-Techne: Bio-Techne's ACD RNAscope provides multiplex in situ hybridization for tissue biomarker detection and the company supplies a wide range of IHC reagents, making it an adjacent incumbent competing for tissue-based biomarker research budgets.
- Agilent Technologies (Dako): Agilent's Dako pathology business supplies IHC reagents, Companion Diagnostic kits, and digital pathology software used in pharma clinical trials and clinical labs — a broad incumbent with overlapping CDx capabilities to Vega's platform.
Direct peers
- Standard BioTools (formerly Fluidigm): Standard BioTools' Hyperion imaging mass cytometry (now part of the merger) enables highly multiplexed, quantitative tissue biomarker readout at subcellular resolution — a competing modality for high-content tissue biomarker work that competes with Vega's multiplex imaging approach.
- NanoString Technologies (Bruker Spatial Biology): NanoString's GeoMx digital spatial profiling and CosMx spatial molecular imaging perform multiplexed, quantitative biomarker analysis on tissue with proprietary chemistry and informatics — a closely analogous 'chemistry + imager + AI' architecture to Vega's platform.
- Akoya Biosciences: Akoya's Phenoptics/Opal platform enables multiplexed, quantitative biomarker detection in tissue via immunofluorescence plus automated image analysis — directly comparable to Vega's nanobead-plus-AI workflow in oncology research and CDx applications.
- Ultivue: Ultivue's inSituPlex multiplexed tissue imaging combines DNA-barcoded antibody probes with signal amplification and AI image analysis for quantitative biomarker detection in oncology — direct mechanistic overlap with Vega's nanobead approach for companion diagnostic use cases.
Emerging players
- 10x Genomics: 10x Genomics' Visium and Xenium spatial omics platforms bring genomics-grade multiplexed, single-cell biomarker resolution to tissue — an adjacent emerging approach that overlaps with Vega's spatial biomarker thesis but uses nucleic-acid rather than protein readouts.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Vega BioImaging social profiles
Digital presenceVega BioImaging financial estimates
Financial estimateRevenue estimate
Valuation estimate
Vega BioImaging leadership team
Management profileNumber of profiles
Profiles8 records
Vega BioImaging funding detail
Funding detailFunding overview
Funding rounds4 records
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Vega BioImaging M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Vega BioImaging
What does Vega BioImaging do?
Vega BioImaging sells an integrated cancer diagnostic platform consisting of a Protein Kit containing patented functionalized alloy nanobeads, an Advanced Optical Scanner based on light-scattering microscopy, and AI-Based Software for automated biomarker quantification. The company also provides companion diagnostic development services and clinical trial support to pharmaceutical companies and clinical/research laboratories for quantitative, multiplexed biomarker detection in oncology.
Is Vega BioImaging a public or private company?
Vega BioImaging is a private company. It is classified as venture growth investor backed and is currently operating.
When was Vega BioImaging founded?
Vega BioImaging was founded in 2021. It employs 1 to 10 people.
Where is Vega BioImaging based?
Vega BioImaging is headquartered in Montréal, Canada, in the North America region.
How does Vega BioImaging make money?
Three revenue lines are on record. Companion Diagnostics Development Services are the primary driver. The others are diagnostic Kits and Hardware and clinical Trial Support Services.
Who are Vega BioImaging's main competitors?
Broad incumbents on record are Revvity (formerly PerkinElmer Life Sciences), Abcam, Roche Diagnostics (Ventana), Bio-Techne and Agilent Technologies (Dako). Direct peers are Standard BioTools (formerly Fluidigm), NanoString Technologies (Bruker Spatial Biology), Akoya Biosciences and Ultivue. 10x Genomics is listed as an emerging player.
Does Vega BioImaging have an API?
No public API is recorded for Vega BioImaging.
What industry is Vega BioImaging in?
Vega BioImaging's product category is Cancer Diagnostics. Its primary akta.pro industry code is HLAAAMAI, Molecular Pathology & Tissue Biomarkers (IHC/ISH, digital pathology-linked markers), with a secondary code of HLAAALAL, Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays). Its NAICS code is 325413 and its SIC code is 2835.